Abstract
Background: The routine inclusion of second-look laparotomy in the management of patients with epithelial ovarian cancer is controversial. At issue is the justification of morbidity incumbent upon surgery and the possible survival benefit of secondary cytoreduction.
Methods: The rate of major complications of surgery was assessed among 100 consecutive patients with FIGO stage III or IV epithelial ovarian cancer who underwent second-look laparotomy. All patients demonstrated a complete clinical and biochemical (CA125 <35 U/ml) response to first-line therapy. Patients were stratified based on findings at surgery. Patients in group 1 (n=37) had a negative second-look laparotomy. Patients in group 2 (n=35) had only microscopically appreciable disease. Patients in group 3 (n=28) had macroscopic disease. Cytoreductive efforts aimed at resection of all macroscopic disease were carried out for patients in group 3.
Results: Thirteen patients (13%) had 15 major complications at surgery. Comparison of the complication rates for patients in groups 1, 2, and 3, of 10%, 8.5%, and 21.4%, respectively, did not achieve statistical significance (p=0.228). The estimated 5-year survival for patients in groups 1, 2, and 3 of 63.9%, 39.8%, and 14.2%, did differ significantly (p<0.0001). Cytoreductive efforts resulted in the resection of all macroscopic disease in 18 of 28 patients (64.2%) in group 3. The median survival for this group of 18 patients was 33 months, and estimated 5-year survival was 20%. These values do not differ significantly from those observed for patients in group 2.
Conclusion: The major complication rate associated with second-look laparotomy is not prohibitive Secondary cytoreductive efforts may result in improved survival for patients with epithelial ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schwarts PE, Smith JP. Second-look operations in ovarian cancer.Am J Obstet Gynecol 1980;138:1124–30.
Podratz KC, Schray MF, Wieand HS, et al. Evaluation of treatment and survival alter positive second-look laparotomy.Gynecol Oncol 1988;31:9–21.
Chambers SK, Chambers JT, Kohorn EI, et al. Evaluation of the role of second-look surgery in ovarian cancer.Obstet Gynecol 1988;72:404–8.
Kaplan EL, Meier P. Nonparametrics estimation from incomplete observations.J Am Stat Assoc 1958;53:457–81.
Potter ME, Hatch KD, Soong SJ, et al. Second-look laparotomy and salvage therapy: a research modality only?Gynecol Oncol 1992;44:3–9.
Luesley D, Blackedge G, Kelly K, et al. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer.Lancet 1988;2:599–603.
Raju KS, McKinna JA, Barker GH, et al. Second-look operations in the planned management of advanced ovarian carcinoma.Am J Obstet Gynecol 1982;144:650–4.
Podratz KC, Kinney WK et al. Second-look operation in ovarian cancer.Cancer 1993;71:1551–8.
Hoskins WJ, Rubin SC, Dulaney E, et al. Influence of second-ary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma.Gynecol Oncol 1989;34:36–71.
Lippman SM, Alberts DS, Slymen DJ, et al. Second-look laparotomy in epithelial ovarian carcinoma.Cancer 1988;61:2571–7.
Miller DS, Spirtos NM, Ballon SC, et al. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma.Cancer 1992;69:502–10.
Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer.Obstet Gynecol 1983;61:189–93.
Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer.Obstet Gynecol 1992;79:168–72.
Morris M, Gershenson DM, Wharton JT, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Gynecol Oncol 1989;34:334–8.
Piver MS, Recio FO, Baker TR, Driscoll D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.Cancer 1994;73:1693–8.
Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer.Cancer 1993;72:1534–40.
Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to <1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.Cancer 1994;74:656–63.
Howell, SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small volume disease treated with intraperitoneal chemotherapy.J Clin Oncol 1987;5:1607–12.
Soper JT, Wilkinson RH Jr, Bandy LC, et al. Intraperitoneal chromic phosphate (P32) as salvage therapy for resistant carcinoma of the ovary after surgical restaging.Am J Obstet Gynecol 1987;156:1153–8.
Morgan L, Chafe W, Mendenhall W, et al. Hyperfractination of whole-abdomen radiation therapy: salvage treatment of persistent ovarian carcinoma following chemotherapy.Gynecol Oncol 1988;31:122–34.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hempling, R.E., Wesolowski, J.A. & Piver, M.S. Second-look laparotomy in advanced ovarian cancer: A critical assessment of morbidity and impact on survival. Annals of Surgical Oncology 4, 349–354 (1997). https://doi.org/10.1007/BF02303586
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303586